Log In
Print this Print this

Biosimilar bevacizumab (CHS-5217)

  Manage Alerts
Collapse Summary General Information
Company Coherus BioSciences Inc.
DescriptionBiosimilar of bevacizumab, a humanized mAb against vascular endothelial growth factor A (VEGF-A)
Molecular Target Vascular endothelial growth factor A (VEGF-A)
Mechanism of ActionAntibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today